Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Blood Cancer J. 2021 Feb 5;11(2):19. doi: 10.1038/s41408-021-00418-2.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Dexamethasone / therapeutic use*
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lenalidomide / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / therapy*
  • Neoplasm, Residual / blood
  • Neoplasm, Residual / diagnosis*
  • Oligopeptides / therapeutic use*
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
  • Transplantation, Autologous

Substances

  • Oligopeptides
  • carfilzomib
  • Dexamethasone
  • Lenalidomide